KalVista Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
KalVista Pharmaceuticals has a total shareholder equity of $172.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $200.2M and $27.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$174.27m |
| Equity | US$172.80m |
| Total liabilities | US$27.40m |
| Total assets | US$200.20m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4XC1's short term assets ($191.6M) exceed its short term liabilities ($22.4M).
Long Term Liabilities: 4XC1's short term assets ($191.6M) exceed its long term liabilities ($5.0M).
Debt to Equity History and Analysis
Debt Level: 4XC1 is debt free.
Reducing Debt: 4XC1 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4XC1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4XC1 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 25.9% each year.